Ovarian Cancer Clinical Trials


Pembrolizumab and Ziv-aflibercept in Treating Patients With Advanced Solid Tumors

Conditions:   Adult Solid Neoplasm;   Metastatic Melanoma;   Metastatic Renal Cell Cancer;   Recurrent Colorectal Carcinoma;   Recurrent Melanoma;   Recurrent Ovarian Carcinoma;   Recurrent Renal Cell Carcinoma;   Stage IV Ovarian Cancer;   Stage IVA Colorectal Cancer AJCC v7;   Stage IVB Colorectal Cancer AJCC v7
Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Biological: Ziv-Aflibercept
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified May 2017

Learn More

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

Conditions:   Hematological Neoplasms;   Non-Hodgkin's Lymphoma;   Hodgkin's Lymphoma;   Lymphoma;   Multiple Myeloma;   Acute Myeloid Leukemia;   Leukemia;   Myelodysplastic Syndromes;   Neoplasms;   Melanoma;   Breast Cancer;   Metastatic Breast Cancer;   Non-Small Cell Lung Cancer;   Small Cell Lung Cancer;   Renal Cell Carcinoma;   Glioblastoma Multiforme;   Osteosarcoma;   Sarcoma;   Thyroid Cancer;   Genitourinary
Interventions:   Drug: CC-486;   Drug: Vidaza
Sponsor:   Celgene
Recruiting - verified July 2017

Learn More

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

Conditions:   Low Grade Ovarian Serous Adenocarcinoma;   Micropapillary Serous Carcinoma;   Ovarian Serous Adenocarcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma
Interventions:   Other: Laboratory Biomarker Analysis;   Drug: Letrozole;   Drug: Paclitaxel;   Drug: Pegylated Liposomal Doxorubicin Hydrochloride;   Other: Pharmacological Study;   Other: Quality-of-Life Assessment;   Drug: Tamoxifen Citrate;   Drug: Topotecan Hydrochloride;   Drug: Trametinib
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified July 2017

Learn More

TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas

Conditions:   Lymphomas;   Solid Tumors;   NSCLC;   Metastatic Colon Carcinoma;   Granulosa Cell Ovarian Cancer
Intervention:   Drug: TRC 102
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified July 24, 2017

Learn More

CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer

Conditions:   Cervical Cancer;   Pancreatic Cancer;   Ovarian Cancer;   Mesothelioma;   Lung Cancer
Interventions:   Drug: Fludarabine;   Biological: Anti-mesothelin CAR;   Drug: Cycolphosphamide;   Drug: Aldesleukin
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified July 19, 2017

Learn More

Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction

Conditions:   Breast Carcinoma;   Carcinoma of Unknown Primary Origin;   Endometrial Carcinoma;   Esophageal Carcinoma;   Lung Carcinoma;   Malignant Head and Neck Neoplasm;   Melanoma;   Ovarian Carcinoma;   Renal Pelvis and Ureter Urothelial Carcinoma;   Testicular Lymphoma
Interventions:   Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Drug: Paclitaxel;   Other: Pharmacological Study;   Drug: Veliparib
Sponsors:   National Cancer Institute (NCI);   Abbott
Recruiting - verified July 2017

Learn More

DICER1-related Pleuropulmonary Blastoma Cancer Predisposition Syndrome: A Natural History Study

Conditions:   Pleuropulmonary Blastoma;   Cystic Nephroma;   Ovarian Sertoli-Leydig Cell Tumors;   Ocular Medulloepithelioma;   Nasal Chondromesenchymal Hamartoma
Intervention:  
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified July 16, 2017

Learn More

Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer

Conditions:   Metastatic Malignant Solid Neoplasm;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Recurrent Primary Peritoneal Carcinoma;   Unresectable Solid Neoplasm
Interventions:   Other: Laboratory Biomarker Analysis;   Other: Pharmacogenomic Study;   Other: Pharmacological Study;   Drug: Topotecan Hydrochloride;   Drug: Veliparib
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified June 2017

Learn More

Cancer Screening and Prevention Program for High Risk Women

Conditions:   Ovarian Cancer;   Breast Cancer
Intervention:  
Sponsors:   New York University School of Medicine;   Lynne Cohen Foundation for Ovarian Cancer Research
Recruiting - verified July 2017

Learn More

61-69 of 69
Results per page

Join the community!


You must be a member of healtheo360 in order to view this group

Register with Email Address

Already a member? Click here to login

healtheo360 believes strongly in user privacy.